Publications

230. Cheung, P., Persson, J., Zhang, B., Vasylovska, S., Lau, J., Invast, S., Korsgren, O., Ståhl, S., Löfblom, J. and Eriksson, O. DGCR2 targeting affibody molecules for delivery of drugs and imaging reagents to human beta cells. Scientific Reports (2024). In press.

229. Dahlsson Leitao, C., Ståhl, S, and Löfblom, J. Surface-engineered bacteria in drug development. Microbial Biotechnol. In: Timmis, K., Ercolini, D., Isazadeh, S., O’Toole, P., Turner R. and Timmis, J. (Eds). The contribution of microbial technologies to Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages. DOI: 10.1111/1751-7915.70033 (2024).

228. Zhang, J., Rinne, S.S., Yin, W., Dahlsson Leitao. C., Björklund, E., Abouzayed, A., Ståhl, S., Löfblom, J., Orlova, A., Gräslund, T. and Vorobyeva, A. Affibody-drug conjugates targeting the human epidermal growth factor receptor 3 demonstrate therapeutic efficacy in mice bearing low expressing xenografts. ACS Pharmacol. Transl. Science https://doi.org/10.1021/acsptsci.4c00402 (2024).

227. Ek, M., Nilvebrant, J., Nygren, P.Å., Ståhl, S., Lindberg, H. and Löfblom, J. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. Frontiers in Immunology DOI:10.3389/fimmu.2024.1437886 (2024).

226. Parks, L., Ek, M., Ståhl, S. and Löfblom, J. Investigation of an AIDA-I based expression system for display of various affinity proteins on Escherichia coli. Biochem. Biophys. Research. Commun. 696, doi.org/10.1016/j.bbrc.2024.149534 (2024).

225. Puuvuori, E., Shen, Y., Hulsart-Billström, G., Mitran, B., Zhang, B., Cheung, P., Wegrzyniak, O., Ingvast, S., Persson, J., Ståhl, S., Korsgren, O., Löfblom, J., Wermeling, F. and Eriksson, O. Non-invasive detection of CD69 positive immune cells before signs of clinical disease in inflammatory arthritis. J. Nucl. Med. DOI: 10.2967/jnumed.123.266336  (2024).

224. Löfblom, J., Hjelm, L.C., Dahlsson Leitao, C., Ståhl, S. and Lindberg, H. Selection of affibody molecules using staphylococcal display. In: Gregg J. Silverman, Christoph Rader & Sachev S. Sidhu (Eds). Advances in Phage Display Collection: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. doi: 10.1101/pdb.prot108401 (2024).

223. Dahlsson Leitao, C., Hjelm, L.C., Ståhl, S., Löfblom, J. and Lindberg, H. Selection of affibody molecules using E. coli display. In: Gregg J. Silverman, Christoph Rader & Sachev S. Sidhu (Eds). Advances in Phage Display Collection: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. doi: 10.1101/pdb.prot108400 (2024).

222. Hjelm, L.C., Dahlsson Leitao, C., Ståhl, S., Löfblom, J. and Lindberg, H. Selection of affibody molecules using phage display. In: Gregg J. Silverman, Christoph Rader & Sachev S. Sidhu (Eds). Advances in Phage Display Collection: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. doi: 10.1101/pdb.prot108399 (2024).

221. Ståhl, S., Hjelm, L.C., Dahlsson Leitao, C., Löfblom, J. and Lindberg, H. Cloning of affibody libraries for display methods. In: Gregg J. Silverman, Christoph Rader & Sachev S. Sidhu (Eds). Advances in Phage Display Collection: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. doi:10.1101/pdb.prot108398 (2024).

220. Ståhl, S., Lindberg, H., Hjelm, L.C., Löfblom, J. and Dahlsson Leitao, C. Engineering of affibody molecules. In: Gregg J. Silverman, Christoph Rader & Sachev S. Sidhu (Eds). Advances in Phage Display Collection: A Laboratory Manual, Second Edition. Cold Spring Harbor Laboratory Press. doi:10.1101/pdb.top107760 (2024).

219. Cheung, P., Thorngren, J., Zhang, B., Vasylovska, S., Lechi, F., Persson, J., Ståhl, S., Löfblom, J., Korsgren, O., Eriksson, J., Lau, J. and Eriksson, O. Preclinical evaluation of affibody molecule for PET imaging of human pancreatic islets derived from stem cells. Eur. J. Nucl. Med. Molec. Imaging Research 13: 107 doi.org/10.1186/s13550-023-01057-3 (2023).

218. Dahlsson Leitao, C., Ståhl, S and Löfblom, J. Bacterial display for selection of affibody molecules. In: Stefan Zielonka & Simon Krah (Eds). Genotype Phenotype Coupling: Methods and Protocols, Methods in Molecular Biology. Springer Science & Business Media, New York. Vol 2681, Chap. 7 pp. 99-112, doi.org/10.1007/978-1-0716-3279-6_7 (2023).

217. Meister, S.W., Parks, L., Kolmar, L., Mestre Borras, A., Ståhl, S. and Löfblom, J. Engineering of TEV protease variants with redesigned substrate specificity. Biotechnology J. doi.org/10.1002/biot.202200625 (2023).

216. Hjelm, L.C., Lindberg, H., Ståhl, S. and Löfblom, J. Affibody molecules intended for receptor-mediated transytosis via the transferrin receptor. Pharmaceuticals 16, 956. doi.org/10.3390/ph16070956 IF5.2 (2023).

215. Dahlsson Leitao, C., Mestre Borras, A., Jonsson, A., Kronqvist, N., Malm, M., Fleetwood, F., Sandersjöö, L., Uhlén, M., Löfblom, J., Ståhl, S. and Lindberg, H. Display of a naïve affibody library on staphylococci for selection of binders by means of flow cytometry sorting. Biochem. Biophys. Research. Commun. 655: 75-81, doi.org/10.1016/ j.bbrc.2023.03.003 (2023).

214. Dahlsson Leitao, C., Mestre Borras, A., Xu, T., Oroujeni, M., Westerberg, C., Clinton, J., Liu, Y., Tolmachev, V., Orlova, A., Ståhl, S., Vorobyeva, A. and Löfblom, J. Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumor selectivity. J. Controlled Release 357: 185-195 (2023).

213. Hjelm, L.C., Lindberg, H., Ståhl, S. and Löfblom, J. Construction and validation of a naïve sequestrin library for directed evolution of binders against aggregation-prone peptides. Int. J. Molec. Sciences 24: 836, doi.org/10.3390/ijms24010836 (2023).

212. Mestre Borras, A., Dahlsson Leitao, C., Ståhl, S. and Löfblom, J. Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting. New Biotechnology 73: 9-18, doi.org/10.1016/j.nbt.2022.12.002 (2023)

211. Rinne, S., Yin, W., Mestre Borras, A., Abouzaed, A., Dahlsson Leitao, C., Vorobyeva, A., Löfblom, J., Ståhl, S., Orlova, A. and Gräslund, T. Targeting tumor cells overexpressing the human epidermal growth factor receptor 3 with potent drug conjugates based on affibody molecules. Biomedicines 10: doi.org/10.3390 (2022).

210. Faresjö, R., Lindberg, H., Ståhl, S., Löfblom, J., Syvänen, S. and Sehlin, D. Transferrin receptor binding BBB-shuttle facilitates brain delivery of anti-Aβ-affibodies. Pharmaceut. Research 39: 1509-1521 doi.org/10.1007/s11095-022-03282-2 (2022).

209. Rinne, S.S., Dahlsson Leitao, C., Abouzayed, A., Vorobyeva, A., Tolmachev, V., Ståhl, S., Löfblom, J and Orlova A. HER3 PET-imaging: 68Ga-labeled affibody molecules provide superior HER3 contrast to 89Zr-labeled antibody and antibody-fragment based tracers. Cancers  13, 4791, doi.org/10.3390/cancers13194791 (2021).

208. Persson, J., Puuvuori, E., Zhang, B., Velikyan, I., Åberg, O., Müller, M., Nygren, P.-Å.,  Ståhl, S., Korsgren, O., Eriksson, O and Löfblom, J. Discovery, optimization and biodistribution of an affibody molecule for imaging of CD69. Sci. Reports  11:19151, doi.org/10.1038/s41598-021-97694-6 (2021).

207. Dahlsson Leitao, C., Rinne, S.S., Altai, M., Vorontsova, O., Dunås, F., Jonasson, P., Tolmachev, V., Löfblom, J., Ståhl, S. and Orlova, A. Evaluating the therapeutic efficacy of mono- and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model. Pharmaceutics12, 551; doi:10.3390/ pharmaceutics 12060551 (2020).

206. Meister, S.W., Hjelm, L., Dannemeyer, M., Tegel, H., Lindberg, H., Ståhl, S. and Löfblom, J. An affibody molecule is actively transported into the cerebrospinal fluid via binding to the transferrin receptor. Int. J. Molec. Sciences21, 2999; doi:10.3390/ijms21082999 (2020).

205. Rinne, S.S., Dahlsson Leitao, C., Saleh-nihad, Z., Mitran, B., Tolmachev, V., Ståhl, S., Löfblom, J. and Orlova, A. Benefit of later-time-point PET imaging of HER3 expression using optimized radiocobalt-labeled affibody molecules. Int. J. Molec. Sciences21, 1972; doi:10.3390/ijms21061972 (2020).

204. Rinne, S.S., Xu, T., Dahlsson Leitao, C., Ståhl, S., Löflom, J., Orlova, A., Tolmachev, V. and Vorobyeva, A. Influene of residualizing properties of the radiolabel on radionuclide molecular imaging of HER3 expression using affibody molecules. Int. J. Molec. Sciences21, 1312; doi:10.3390/ijms21041312 (2020).

203. Rinne, S.S., Dahlsson Leitao, C., Gentry, J., Mitran, B., Abouzayed, A., Tolmachev, V., Ståhl, S., Löfblom, J. and Orlova, A. Increase in negative charge of the 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Scientific Reports9:17710doi: 10.1038 /s41598-019-54149-3 (2019) 

202. Boutajangout, A., Lindberg, H., Awwad, A., Paul, A., Baithalmal, R., Almokyad, I., Höidén-Guthenberg, I., Gunneriusson, E., Frejd, F.Y., Härd, T., Löfblom, J., Ståhl, S. and Wisniewski, T. Affibody-mediated sequestration of amyloid ß demonstrates preventive efficacy in a transgenic Alzheimer's disease model. Frontiers Aging Neuroscience, 11: 64,doi:10.3389/fnagi.2019.00064 (2019).

201. Rosestedt, M., Andersson, K.G., Rinne, S.S., Dahlsson Leitao, C., Mitran, B., Vorobyeva, A., Ståhl, S., Löfblom, J., Tolmachev V. and Orlova, A. Improved contrast of affibody-mediated imaging of HER3-expression in mouse xenograft model through coinjection of a trivalent affibody for in vivo blocking of hepatic uptake. Scientific Reports6:6779 doi.org/10.1038/s41598-019-43145-2 (2019).

200. Dahlsson Leitao, C., Rinne, S.S., Mitran, B., Vorobyeva, A., Andersson, K.G., Tolmachev, V., Ståhl, S., Löfblom, J. and Orlova, A. Molecular design of HER3-targeting affibody molecules: Influence of chelator and presence of HEHEHE-tag on biodistribution of 68Ga-labeled tracers. Int.J. Molec. Sciences, 20,doi:10.3390/ ijms20051080 (2019).

199. Rinne, S.S., Dahlsson Leitao, C., Mitran, B., Bass, T.Z., Andersson, K.G., Tolmachev, V., Ståhl, S., Löfblom, J. and Orlova, A. Optimization of HER3 expression imaging using affibody molecules: influence of chelator for labelling with indium-111. Scientific Reports, 9: 655, doi:10.1038/s41598-018-36827 (2019).

198. Mitran, B., Andersson, K.G., Lindström, E., Garousi, J., Rosestedt, M., Tolmachev, V., Ståhl, S., Orlova, A. and Löfblom, J. Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377.Oncol. Reports41:534-542 (2019).

197. Andersson, K.G., Persson, J., Ståhl, S. and Löfblom, J. Autotransporter-mediated display of a naïve affibody library on the outer membrane of E. coli. Biotech. J. e1800359,doi 10.1002/biot.201800359 (2019). 

196.Altai, M., DahlssonLeitao, C., Rinne, S.S., Vorobyeva, A., Atterby, C., Ståhl, S., Tolmachev, V., Löfblom, J. and Orlova, A. Influence of molecular design on the targeting properties of ABD-fused mono- and bivalent anti-HER3 affibody therapeutic constructs. Cells7: 164; doi:10.3390/cells7100164 (2018).

195. Orlova, A., Bass, T.Z., Rinne, S.S., Dahlsson Leitao, C., Rosestedt, M., Atterby, C., Gudmundsdotter, L., Frejd, F.Y., Löfblom, J., Tolmachev, V. and Ståhl, S. Evaluating the therapeutic potential of a dimeric HER3-binding affibody construct TAM-HER3 in comparison with a monoclonal antibody, seribantumab. Molec. Pharmaceutics15:3394-3403 (2018).

194. Mitran, B., Güler, R., Roche, F.P., Lindström, E., Kumar Selvaraju, R., Fleetwood, F., Rinne, S., Claesson-Welsh, L., Tolmachev, V., Ståhl, S., Orlova, A. and Löfblom J. Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in murine model. Theranostics 8: 4464-4476 (2018).

193. Rosestedt, M., Andersson, K.G., Mitran, B., Rinne, S.S., Tolmachev, V., Löfblom, J., Orlova, A., and Ståhl, S. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 (HER3) expression. Internat.J. Oncol.51:1765-1774 (2017).

192. Löfblom, J., Rosenstein, R., Nguyen, M.T., Ståhl, S. and Götz, F. Staphylocoocus carnosus, from starter culture to protein engineering platform. Appl. Microbiol. Biotechnol.101:8293-8307(2017).

191. Garousi, J., Anderson, K.G., Dam, J.H., Olsen, B.B., Mitran, B., Orlova, A., Buijs, J., Löfblom, J., Ståhl, S., Thisgaard, H., and Tolmachev, V. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated affibody molecule. ScientificReports DOI:10.1038/s41598-017-05700-7 (2017).

190. Wahlberg, E., Rahman, M.M., Lindberg, H., Gunneriusson, E., Schmuck, B., Lendel, C., Sandgren, M., Löfblom, J., Ståhl, S. and Härd, T. Identification of proteins that specifically recognize and bind protofibrillar aggregates of amyloid-ß. Scientific Reports7:5949 DOI:10.1038/s41598-017-06377-8 (2017).

189.Ståhl, S., Gräslund, T., Eriksson-Karlström, A., Frejd, F.Y., Nygren, P.-Å. and Löfblom, J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 35:691-712(2017).

188. Bass, T.Z., Rosestedt, M., Mitran, B., Frejd, F.Y., Löfblom, J., Tolmachev, V. Ståhl, S. and Orlova, A. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Scientific Reports7:43118. DOI: 10.1038/srep43118 (2017).

187. Lindberg, H., Sandersjöö, L., Meister, S., Uhlén, M., Löfblom, J. and Ståhl, S. Flow-cytometric screening of aggregation-inhibitors using a fluorescence-assisted intracellular method. Biotech. J. DOI: 10.1002/biot.201600364. (2017).

186. Andersson, K., Oroujeni, M., Garousi, J., Mitran, B., Ståhl, S., Orlova, A., Löfblom, J. and Tolmachev, V. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labelled with 99mTc using a peptide-based cysteine-containing chelator. Internat.J. Oncol.49:2285-2293(2016).

185. Cheng, Q., Wållberg, H., Grafström, J., Lu, L., Thorell, J.-O., Hägg-Olofsson, M., Linder, S., Johansson, K., Tegnebratt, T., Arnér, E.S.J., Stone-Elander, S., Martinsson-Ahlzén, H.S. and Ståhl, S. Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged affibody-based tracer to estimate the specific uptake.Eur. J. Nucl. Med. Mol. Imaging,DOI: 10.1186/s13550-016-0213-8 (2016).

184. Malm, M., Frejd, F.Y., Ståhl, S. and Löfblom, J. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. mAbs8:1195-1209 (2016).

183. Garousi, J., Andersson, K.G., Mitran, B., Pichl, M.-L., Ståhl, S., Orlova, A., Löfblom, J. and Tolmachev, V. PET imaging of EGFR expression in tumours using 89Zr-labelled ZEGFR:2377affibody molecules. Int. J. Oncol.48:1325-1332 (2016).

182. Fleetwood, F., Güler, R., Gordon, E., Ståhl, S., Claesson-Welsh, L. and Löfblom, J. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. Cell. Molec. Life Sciences. 73:1671-1683 (2016). 

181.Rosestedt, M., Andersson, K.G., Mitran, B., Tolmachev, V., Löfblom, J., Orlova, A. and Ståhl, S. Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific Reports5:15226 DOI: 10.1038/srep15226 (2015).

180. Ståhl, S. Next-generation of engineered proteins in life science. Editorial. (Eds. A. Denis and C. Mérial-Kieny) Keratin 21: 4-7 (2015).

179. Lindberg, H., Härd, T., Löfblom, J. and Ståhl, S. A truncated and dimeric format of an affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity. Biotechnol. J.10:1707-1718 (2015).

178. Andersson, K.G., Rosestedt, M., Varasteh, Z., Malm, M., Sandström, M., Tolmachev, V., Löfblom, J., Ståhl, S. and Orlova, A. Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncol. Reports 34:1042-1048(2015).

177. Fleetwood, F., Klint, S., Hanze, M., Gunneriusson, E., Frejd, F.Y., Ståhl, S. and Löfblom J. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic affibody molecules results in dramatically improved affinity. Scientific Reports 4:7518-7521(2014).

176. Fleetwood, F., Andersson, K.G., Ståhl, S. and Löfblom, J. An engineered autotransporter-based surface expression vector enables efficient display of Affibody molecules on OmpT-negative E. colias well as protease-mediated secretion in OmpT-positive strains. Microbial. Cell Factories13:179-191 (2014).

175. Altai, M., Wållberg, H., Honarvar, H., Strand, J., Orlova, A., Varasteh, Z., Sandström, M., Löfblom, J., Larsson, E., Strand, S.-E., Lubberink, M., Ståhl, S. and Tolmachev, V. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. J. Nucl. Med. 55: 1842-1848(2014).

174. Orlova, A., Malm, M., Rosestedt, M., Varasteh, Z., Andersson, K., Selvaraju, R.K., Ståhl, S., Altai, M., Honarvar, H., Strand, J., Tolmachev, V. and Löfblom, J. Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)-HEHEHE-Z08698affibody molecule. Eur. J. Nucl. Med. Mol. Imaging 41: 1450-1459 (2014).

173. Malm, M., Bass, T., Gudmundsdotter, L., Lord, M., Frejd, F.Y., Ståhl, S. and Löfblom, J. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotech. J.9:1215-1222 (2014).

172. Altai, M., Honarvar, H., Wållberg, H., Strand, J., Varasteh, Z., Orlova, A., Dunås, F., Löfblom, J., Tolmachev, V. and Ståhl, S. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. Eur. J. Medicinal Chem.87:519-528 (2014).

171. Ståhl, S., Kronqvist, N., Jonsson A. and Löfblom J. Affinity proteins and their generation. J. Chemical Technol. & Biotechnol.88:25-38 (2013).

170. Nguyen, T.N., Libon, C. and Ståhl, S. Subunit vaccine candidates engineered from the central conserved region of the RSV G protein aimed for parenteral or mucosal delivery. In:M. Giese (Ed) Springer Verlag, Wien. Molecular Vaccines – from Prophylaxis to Therapy. Vol. 1 (2013) 103-118.

169. Wållberg, H. and Ståhl, S. Design and evaluation of radiolabelled tracers for imaging of HER2-expressing tumors. Biotechnol. Applied Biochem. 60: 365-383 (2013).

168. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L., Bass, T., Frejd, F.Y., Höidén-Guthenberg, I., Varasteh, Z., Orlova, A., Tolmachev, V., Ståhl, S. and Löfblom, J. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error prone PCR-like diversification. PLoS One10:8(5):e62791 (2013).

167. Lindberg, H., Johansson, A., Härd, T., Löfblom, J. and Ståhl S. Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid ß-peptide.Biotechnol. J. 6:1115-1129 (2013).

166. Fleetwood, F., Devoogdt, N., Pellis, M., Wernery, U., Muyldermans, S., Ståhl, S. and Löfblom, L. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell. & Molec. Life Sciences70:1081-1093(2013).

165. Ekerljung, L., Wållberg, H., Sohrabian, A., Anderson, K., Friedman, M., Frejd, F.Y., Ståhl, S. and Gedda, L. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2. Bioconjugate Chem.23:1802-1811 (2012).

164. Wållberg, H., Grafström, J., Cheng, Q., Lu, L., Martinsson Ahlzén, H.-S., Samén, E., Thorell, J.-O., Johansson, K., Dunås, F., Hägg Olofsson, M., Stone-Elander, S., Arnér, E. and Ståhl, S. HER2-positive tumors imaged within one hour using a site-specifically 11C-labeled Sel-tagged Affibody molecule. J. Nucl. Med.53:1446-1453 (2012). 

163. Göstring, L., Malm, M., Höidén-Guthenberg, I., Frejd, F., Ståhl, S., Löfblom, J. and Gedda, L. Cellular effects of HER3-specific Affibody molecules. PLoS One 7:e40023 (2012). 

162. Cheng, Q., Lu, L., Grafström, J., Olofsson, M.H., Thorell, J.O., Samén, E., Johansson, K., Ahlzén, H.S., Stone-Elander, S., Linder, S. and Arnér, E.S.; Sel-tag Imaging Project (Corporate author: Cheng, Q., Wållberg, H., Johansson, K., Ahlzén, H.S., Arnér, E.S., Lindberg, H., Fleetwood, F., Löfblom, J., Ståhl, S., Lu, L., Grafström, J., Thorell, J.O., Samén, E., Stone-Elander, S., Hägg, M., Linder, S., Nilsson, S.). Combining [(11)C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS One 7: e42151 (2012). 

161. Lindberg, H., Hofström, C., Altai, M., Honorvar, H., Wållberg, H., Orlova, A., Ståhl, S., Gräslund, T., and Tolmachev, V. Evaluation of a HER2-targeting Affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C-terminus.Tumor Biology 33:641-651 (2012). 

160. Altai, M., Wållberg, H., Orlova, A., Rosestedt, M., Hosseinimehr, S.J., Tolmachev, V. and Ståhl, S. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant affibody molecules. Amino Acids42:1975-1985 (2012).

159. Löfblom, J., Frejd, F.Y. and Ståhl, S. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol.22:843-848 (2011).

158. Kronqvist, N., Malm, M., Gunneriusson, E., Nilsson, M., Höidén-Guthenberg, I., Frejd, F., Ståhl, S. and Löfblom, J. Combining phage and staphylococcal selection for the generation of ErbB3-binding affibody molecules. Prot. Engin. Design Select.24:385-396 (2011).

157. Wållberg, H., Orlova, A., Altai, M., Jalal Hosseinimehr, S., Widström, C., Malmberg, J., Ståhl, S. and Tolmachev, V. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J. Nucl. Med.52:461-469 (2011).

156. Wållberg, H., Löfdahl, P.-Å., Tschapalda, K., Uhlén, M., Tolmachev, V., Nygren, P.-Å. and Ståhl, S.Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.Protein Expr. Purif.76:127-135 (2011).

155. Ståhl, S., Friedman, M., Carlsson, J., Tolmachev, V. and Frejd, F. Affibody molecules for targeted radionuclide therapy.  In: T.W. Speer (Ed.) Lippincott. Targeted Radionuclide Therapy (2011) 49-58.

154. Luheshi, L.M., Hoyer, W., de Barros, T.P., van Dijk Härd, I., Brorsson, A.C., Macao, B., Persson, C., Crowther, D.C., Lomas, D.A., Ståhl, S., Dobson, C.M. and Härd, T. Sequestration of the Aß peptide prevents toxicity and promotes degradation in vivo. PLoS Biology8: e1000334(2010). 

153. Rockberg, J., Löfblom, J., Hjelm, B., Ståhl, S. and Uhlén, M. Epitope mapping using bacterial surface display. Curr. Protocols Immunol. 90:9.9.1-9.9.17 (2010).

152.Kronqvist, N., Malm, M., Rockberg, J., Hjelm, B., Uhlén, M., Ståhl, S. and Löfblom, J. Staphylococcal surface display in combinatorial protein engineering and epitope mapping of antibodies.In: S. Shibasaki and M. Ueda (Eds.) Recent Patents in Biotechnology. 4:171-182 (2010).

151. Hjelm, B., Rockberg, J., Díez Fernández, C., Löfblom, J., Ståhl, S., Johannesson, H. and Uhlén, M. Exploring epitopes of antibodies toward the human tryptophanyl-tRNA synthetase. New Biotechnology 27:129-137 (2010).

150. Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S.and Frejd, F.Y.Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters 584: 2670-2680 (2010).

149. Friedman, M., Lindström, S., Ekerljung, L., Andersson-Svahn, H., Carlsson, J., Brismar, H., Gedda, L., Frejd, F.Y. and Ståhl, S. Engineering and characterization of a bispecific HER2xEGFR-binding affibody molecule. Biotechnol. Applied Biochem. 54:121-131 (2009).

148. Jonsson, A., Wållberg, H., Herne, N., Ståhl, S. and Frejd, F.Y.Generation oftumor necrosis factor -specific affibody molecules capable of blocking receptor binding in vitro.Biotechnol. Applied Biochem.54:93-103 (2009).

147. Grönwall, C. and Ståhl, S. Engineered affinity proteins – generation and applications. J. Biotechnol.140:254-269 (2009).

146. Kronqvist, N., Rockberg, J., Hjelm, B., Ståhl, S., Uhlén, M. and Löfblom, J. Emerging techniques using surface display on gram-positive bacteria for combinatorial protein engineering and characterization. BIOforum Europe4:22-24 (2009).

145. Friedman, M. and Ståhl, S. Engineered affinity proteins for tumor targeting applications. Biotechnol. Applied Biochem. 53:1-29 (2009).

144. Myhre, S., Henning, P., Friedman, M., Ståhl., S., Lindholm, L. and Magnusson, M.K. Re-targeted adenovirus vectors with dual specificity; binding
 specificities conferred by two different affibody molecules in the fiber.Gene Therapy16:252-261 (2009).

143. Tolmachev, V., Friedman, M., Sandström, M., Eriksson, T., Rosik, D., Hodik, M., Ståhl, S., Nilsson, F.Y. and Orlova, A. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J. Nuclear Med. 50:274-283(2009).

142. Rockberg, J., Löfblom, J., Hjelm, B., Uhlén, M., and Ståhl, S. Epitope mapping of antibodies using bacterial surface display. Nature Methods5:1037-1045 (2008).

141. Grönwall, C., Snelders, E., Jarelöv-Palm, A., Eriksson, F., Herne, N. and Ståhl S. Generation of affibody ligands binding the interleukin 2-receptor alpha / CD25. Biotechnol. Applied Biochem.50:97-112 (2008).

140. Hoyer, W., Grönwall, C., Jonsson, A., Ståhl, S. and Härd, T. Stabilization of a ß-hairpin in monomeric Alzheimer’s amyloid-ß peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. USA 105: 5099-5104 (2008).

139. Nordberg, E., Orlova, A., Friedman, M., Tolmachev, V., Ståhl, S., Nilsson, F.Y., Glimelius, B. and Carlsson, J. In vivoand in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2in EGFR expressing tumor cells. Oncology Reports19:853-857 (2008).

138. Kronqvist, N., Löfblom, J., Jonsson, A., Wernérus, H. and Ståhl, S. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Prot. Eng. Design Select.21: 247-255 (2008). 

137. Friedman, M., Orlova, A., Johansson, E., Eriksson, T., Höidén-Guthenberg, I., Nilsson, F.Y., Tolmachev, V. and Ståhl, S. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding Affibody molecule. J. Mol. Biol. 376: 1388-1402 (2008).

136. Kronqvist, N., Löfblom, J., Severa, D., Ståhl, S. and Wernérus, H. Simplified characterization through site-specific protease-mediated release of affinity proteins selected by staphylococcal display. FEMS Microbiol. Lett.278:128-136 (2008).

135. Grönwall, C., Sjöberg, A., Ramström, M., Höidén-Guthenberg, I., Hober, S., Jonasson, P. and Ståhl S. Affibody-mediated transferrin depletion for proteomics applications. Biotechnol. J.2:1389-1398 (2007).

134. Ståhl, S., Nilsson, F.Y., Friedman, M., Feldwisch, J., Wennborg, A., Wikman, M., Orlova, A., Tolmachev, V., Carlsson, J. and Abrahmsén, L.Affibody molecules for tumor targeting applicationsIn: J. Wilce (Editor)Proceedings of the 4th international Peptide Symposium, in conjunction with the 7th Australian Peptide Conference and the 2nd Asia-Pacific International Peptide Symposium, www.peptideoz.org (2007).

133. Löfblom, J., Sandberg, J., Wernérus, H. and Ståhl, S. Evaluation of staphylococcal cell surface display and flow cytometry for postselectional chracterization of affinity proteins in combinatorial protein engineering applications. Applied Environ. Microbiol.73:6714-6721 (2007).

132. Nordberg, E., Friedman, M., Göstring, L., Adams, G.P., Brismar, H., Nilsson, F.Y., Ståhl, S., Glimelius, B. and Carlsson, J. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule Nuclear Med. Biol. 34: 609-618 (2007).

131. Falk, R., Ramström, M., Ståhl, S. and Hober, S. Approaches for systematic proteome exploration. Biomolecular Engineering24: 155-168 (2007).

130. Friedman, M., Nordberg, E., Höidén-Guthenberg, I., Brismar, H., Adams, G.P., Nilsson, F.Y., Carlsson, J. and Ståhl, S. Phage display selection of affibody molecules binding to the extracellular domain of the epidermal growth factor receptor. Prot. Eng. Design Select.20:189-199(2007).

129.Magnusson, M., Henning, P., Myhre, S., Wikman, M., Uil, T.G., Friedman, M., Andersson, K.E., Hong, S.S., Hoeben, R., Habib, N.A., Ståhl, S., Boulanger, P. and Lindholm, L. An Adenovirus 5 vector genetically re-targeted by an affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Therapy14:468-479 (2007).

128. Pinitkiatisakul S., Friedman, M., Wikman, M., Mattsson, J.G., Lövgren Bengtsson, K., Ståhl, S and Lundén, A. Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations. Vaccine25:3658-3668 (2007).

127. Grönwall, C., Jonsson, A., Lindström, S., Gunneriusson, E., Ståhl, S. and Herne, N. Selection and characterization of affibody ligands binding to Alzheimer amyloid ß peptides. J. Biotechnol.128:162-183 (2007). 

126. Löfblom, J., Kronqvist, N., Uhlén, M., Ståhl, S. and Wernérus, H. Optimization of electroporation-mediated transformation: Staphylococcus carnosusas model organism. J. Applied Microbiol.102: 736-747 (2007).

125. Steffen, A.-C., Orlova, A., Wikman, M., Nilsson, F.Y., Ståhl, S., Adams, G.P., Tomalchev, V. and Carlsson, J. Affibody-mediated tumor targeting of HER-2 expressing xenografts in mice. Eur.J. Nucl. Med. Mol. Imaging 33:631-638(2006).

124. Wikman M., Friedman M., Pinitkiatisakul S., Andersson, C., Lövgren-Bengtsson. K., Lundén, A. and Ståhl, S. Achieving directed iscom incorporation. Expert Review of Vaccines5:395-403 (2006).

123. Wikman, M., Rowcliffe, E., Friedman, M., Henning, P., Lindholm, L., Olofsson, S. and Ståhl, S. Selection and characterization of an HIV-1 gp120-bindning affibody ligand. Biotechnol. Applied Biochem.45:93-103 (2006).

122. Orlova, A., Magnusson, M., Eriksson, T., Nilsson, M., Larsson, B., Höiden-Guthenberg, I., Carlsson, J., Tolmachev, V., Ståhl, S. and Nilsson, F.Y.Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Research66:4339-4348 (2006).

121. Orlova, A., Nilsson, F., Wikman, M., Widström, C., Ståhl, S., Carlsson, J. and Tolmachev, V. Comparative in vivoevaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J. Nuclear Medicine47:512-519 (2006).

120. Löfblom, J., Wernérus, H. and Ståhl, S. Fine affinity discrimination by normalized fluorescence activated cell sorting in staphylococcal surface display. FEMS Microbiol. Letters248:189-198 (2005).

119. Steffen, A.-C., Wikman, M., Tolmachev, V., Adams, G.P., Nilsson, F., Ståhl, S. and Carlsson, J. In vitrocharacterization of a bivalent anti-HER-2 affibody with potential for radionuclide based diagnostics. Cancer Biother. Radiopharmaceut.20:239-247 (2005).

118. Pinitkiatisakul S., Mattsson, J.G., Wikman, M., Friedman, M., Lövgren Bengtsson, K., Ståhl, S and Lundén, A. Immunization of mice against neosporosis with recombinant NcSRS2 iscoms. Veterinary Parasitology129:25-34 (2005).

117. Wikman M., Friedman M., Pinitkiatisakul S., Hemphill, A., Lövgren-Bengtsson. K., Lundén, A. and Ståhl, S. Applying biotin-streptavidin binding for iscom association of recombinant immunogens. Biotechnol. Applied Biochem.41:163-174 (2005).

116. Wikman M., Friedman M., Pinitkiatisakul S., Andersson, C., Hemphill, A., Lövgren-Bengtsson. K., Lundén, A. and Ståhl, S. General strategies for efficient adjuvant incorporation of recombinant subunit immunogens. Vaccine23:2331-2335 (2005).

115. Qazi, K. R., Wikman, M., Vasconcelos, N.-M., Berzins, K., Ståhl, S. and Fernández, C. Enhancement of DNA vaccine potency by linkage of Plasmodium falciparummalarial antigen gene fused with a fragment of HSP70 gene. Vaccine 23:1114-1125(2005).

114.Wernérus, H. and Ståhl, S. Biotechnological applications for surface-engineered bacteria. Biotechnol. Applied Biochem.40:209-228 (2004).

113. Wikman, M., Steffen, A.-C., Gunneriusson, E., Tomlmachev, V., Adams, G.P., Carlsson, J. and Ståhl, S. Selection and characterization of HER2/neu-binding affibody ligands. Prot. Engin. Design Select. 17:455-462(2004).

112. Falk, R., Agaton, C., Kiesler, E., Jin, S., Wieslander, L., Visa, N., Hober S. and Ståhl, S. An improved dual expression concept generating high-quality antibodies for proteomics research. Biotechnol. Applied Biochem.38:231-239 (2003).

111. Wernérus, H., Samuelson, P. and Ståhl, S. Fluorescence activated cell sorting of specific affibody-displaying staphylococci. Applied. Environ. Microbiol.69:5328-5335 (2003).

110. Agaton, C., Galli, J., Höidén-Guthenberg, I., Janzon, L., Hansson, M., Asplund, A., Brundell, E., Lindberg, S., Ruthberg, I., Wester, K., Wurtz, D., Höög, C., Lundeberg, J., Ståhl, S., Pontén, F. and Uhlén, M. Affinity proteomics for systematic profiling of chromosome 21 gene products in human tissues. Molec. Cell. Proteomics.2:405-414 (2003).

109. Hober, S., Linhult, M., Gülich, S., Sjöberg, A., Nord, K. and Ståhl, S. Stabilization of protein domains towards alkaline conditions. In: V. Sedgwick (Ed.) Extended reports from the 2ndinternational symposium on downstream processing and genetically engineered antibodies and related molecules. (2003) 32-34.

108. Ståhl, S., Hober, S., Nilsson, J., Uhlén, M. and Nygren, P.-Å. Genetic approaches to facilitate purification. In:B. Mattiasson and R. Hatti-Kaul (Eds.) Isolation and purification of proteins. Marcel Dekker Inc., New York. (2003) 95-129.

107. Gühlich, S., Linhult, M., Ståhl, S. and Hober, S., Engineering of streptococcal protein G for increased alkaline stability. Protein Engin.15:835-842 (2002).

106. Gräslund, S., Larsson, M., Falk, R., Uhlén, M., Höög C. and Ståhl, S. Single vector three-frame expression systems for affinity-tagged proteins. FEMS Microbiol. Lett.215:139-147 (2002).

105. Andersson, C., Wikman, M., Lövgren-Bengtsson, K. and Ståhl, S. Hydrophobic tagging of immunogens for iscom incorporation. In:M. P. Weiner and Q. Lu (Eds.) Gene Cloning and Expression Technologies. Eaton Publishing Co., Westborough, MA. (2002) 251-265.

104. Gräslund, S., Eklund, M., Falk, R., Uhlén, M., Nygren, P.-Å. and Ståhl, S. A novel affinity gene fusion system allowing protein A-based recovery of non-immunoglobulin gene products. J. Biotechnol. 99:41-50 (2002).

103. Hansson, M., Samuelson, P., Nguyen, T. N. and Ståhl, S. General expression vectors for Staphylococcus carnosusallowed efficient production of the outer membrane protein A of Klebsiella pneumoniae. FEMS Microbiol. Lett.210:263-270 (2002).

102. Wernérus, H., Lehtiö, J., Samuelson P. and Ståhl, S. Engineering of staphylococcal surfaces for biotechnological applications. J. Biotechnol.96:67-78 (2002).

101. Wernérus, H. and Ståhl, S. Vector engineering to improve a staphylococcal surface display expression system. FEMS Microbiol. Lett. 212:47-54 (2002).

100. Samuelson, P., Gunneriusson, E., Nygren, P.-Å. and Ståhl, S. Display of proteins on bacteria. J. Biotechnol.96:129-154 (2002).

99. Rönnmark, J., Hansson, M., Nguyen, T., Uhlén, M., Robert, A., Ståhl, S., and Nygren, P-Å.Construction and characterization of affibody-Fc chimeras produced in Escherichia coli. J. Immunol. Meth.261:199-211(2002).

98. Gräslund, S., Falk, R., Brundell, E., HöögC. and Ståhl, S. A high-stringency proteomics concept aimed for generation of antibodies specific for cDNA-encoded proteins. Biotechnol. Applied Biochem.35:75-82 (2002).

97. Jonasson, P., Liljeqvist, S., Nygren, P.-Å. and Ståhl, S. Genetic design for facilitated production and recovery of recombinant proteins in Escherichia coli. Biotechnol. Applied Biochem.35:91-105 (2002).

96. Ståhl, S. and Liljeqvist, S. Vaccines: subunit.In: S.Robertson (Ed.) Encyclopedia of Life Sciences, Vol. 19, Nature Publishing Group, Macmillan Reference Ltd., London, UK. (2001) 155-164.

95. Wernérus, H., Lehtiö, J., Teeri, T., Nygren, P.-Å. and Ståhl, S. Generation of metal-binding staphylococci through surface display of engineered cellulose-binding domains. Appl. Environ. Microbiol. 67:4678-4684 (2001).

94. Andersson, C., Hansson, M., Power, U., Nygren, P.-Å. and Ståhl, S. Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine using a product-specific affinity column. Biotechnol. Applied Biochem.34:25-32 (2001).

93. Andersson, C., Wikman, M., Lövgren-Bengtsson, K., Lundén, A. and Ståhl, S. In vivoand in vitro lipidation of recombinant immunogens for direct iscom incorporation. J. Immunol. Methods255:135-148 (2001).

92. Andersson, C., Vasconcelos, N.-M., Sievertzon, M., Haddad, D., Liljeqvist, S., Berglund, P., Liljeström, P., Ahlborg, N., Ståhl, S. and Berzins, K. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparumantigen Pf332. Scand. J. Immunol.54:117-124(2001).

91. Lehtiö, J., Wernérus, H., Samuelson, P., Teeri, T. and Ståhl, S. Directed immobilization of recombinant staphylococci on cotton fibers by functional display of a fungal cellulose-binding domain. FEMS Microbiol. Letters195:197-204 (2001).

90. Jörgensen, P-M., Gräslund, S., Betz, R., Ståhl, S., Larsson, C. and Höög, C. Characterization of the human APC1, the largest subunit of the anaphase promoting complex. Gene262:51-59 (2001).

89. Hansson, M., Samuelson, P., Gunneriusson, E. and Ståhl, S. Surface display on gram positive bacteria. Combinatorial Chemistry & High Throughput Screening 4:171-184 (2001).

88. Andersson, C., Liljeström, P., Ståhl, S. and Power, U. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunizaion encoding a secreted RSV G-protein derived antigen. FEMS Immunol. Med. Microbiol. 29:247-253(2000).

87. Ståhl, S., Robert, A., Gunneriusson, E., Wernérus, H., Cano, F., Liljeqvist, S., Hansson, M., Nguyen, T.N. and Samuelson, P. Staphylococcal surface-display and its applications. Int. J. Med. Microbiol.290:571-577 (2000).

86. Larsson, M., Norrander, J., Gräslund, S., Brundell, E., Linck, R., Ståhl, S. and Höög, C. Spatial and temporal expression of Tekt1, a mouse tektin C homologue, during spermatogenesis suggests that it is involved in the development of the sperm tail basal body and axoneme. Eur. J. Cell Biol.79:718-725 (2000).

85. Hansson, M., Nygren, P.-Å. and Ståhl, S. Design and production of recombinant subunit vaccines. Biotechnol. Applied Biochem. 32: 95-107 (2000).

84. Larsson, M., Gräslund, S., Yuan, L., Brundell, E., Uhlén, M., Höög, C. and Ståhl, S. High-throughput protein expression of cDNA products as a tool in functional genomics. J. Biotechnol. 80: 143-157(2000).

83. Goetsch, L., Plotnicky-Gilquin, H., Champion, T., Beck, A., Corvaïa, N., Ståhl, S., Bonnefoy, J.-Y., Nguyen, T.N. and Power, U.F. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate. Vaccine18: 2735-2742(2000).

82. Cano, F., Plotnicky-Gilquin, H., Nguyen, T.N., Liljeqvist, S., Samuelson, P., Bonnefoy, J.-Y., Ståhl, S. and Robert, A. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization with live staphylococci with surface-displayed RSV-peptides. Vaccine 18: 2743-2752(2000).

81. Andersson, C., Sandberg, L., Wernérus, H., Johansson, M., Lövgren-Bengtsson, K. and Ståhl, S. Improved systems for production of hydrophobically tagged immunogens for efficient iscom incorporation. J. Immunol. Meth. 238: 181-193(2000).

80. Ståhl, S. Recombinant strategies for improved delivery of protein drugs and subunit vaccines.Acta Technologiae et Legis Medicamenti 11: 13-22 (2000).

79. Samuelson, P., Wernérus, H., Svedberg, M. and Ståhl, S. Staphylococcal surface-display of metal-binding polyhistidyl peptides. Appl. Environ. Microbiol.66:1243-1248 (2000).

78. Larsson, M., Ståhl, S., Uhlén, M. and Wennborg, A. Expression profile viewer (ExProView) - a universal tool for transcriptome analysis. Genomics 63:341-353 (2000).

77. Jonasson, P., Nygren, P.-Å., Jörnvall, H., Johansson, B.-L., Wahren, J., Uhlén, M. and Ståhl, S. An integrated bioprocess for production of the human proinsulin C-peptide via heat release of an intracellular heptameric fusion protein. J. Biotechnol.76:215-226 (2000).

76. Rigler, R., Pramanik, A., Jonasson, P., Kratz, G., Jansson, O., Nygren, P.-Å., Ståhl, S., Ekberg, K., Johansson, B.-L., Uhlén, S., Uhlén, M., Jörnvall, H. and Wahren, J. Specific binding of proinsulin C-peptide to human cell membranes. Proc. Natl. Acad. Sci. USA23: 13319-13323 (1999).

75. Samuelson, P., Cano, F., Robert, A. and Ståhl, S. Engineering of a Staphylococcus carnosussurface-display system by substition of deletion of a Staphylococcus hyicuslipase propeptide. FEMS Microbiol. Lett.179:131-139 (1999).

74. Larsson, M., Brundell, E., Jörgensen, P.-M., Ståhl, S. and Höög, C. Characterization of a novel nucleolar protein that transiently associates with condensed chromosomes in mitotic cells. Eur. J. Cell Biol. 78: 382-390 (1999).

73. Gunneriusson, E., Samuelson, P., Ringdahl, J., Grönlund, H., Nygren P.-Å. and Ståhl, S. Staphylococcal surface-display of immunoglobulin A (IgA) and IgE-specific in vitroselected binding proteins (affibodies) based on Staphylococcus aureusprotein A. Appl. Environ. Microbiol.65: 4134-4140 (1999).

72. Gräslund, S., Larsson, M., Sterky, F., Uhlén, M., Lundeberg, J., Höög, C. and Ståhl, S. Recovery of upstream cDNA sequences by a PCR-based biotin-capture method. BioTechniques 27: 173-179(1999).

71. Liljeqvist, S. and Ståhl, S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems or nucleic acid vaccines. J. Biotechnol. 73:1-33 (1999).

70. Andréoni, C., Goetsch, L., Libon, C., Samuelson, P., Robert, A., Nguyen, T.N., Uhlén, M., Binz, H. and Ståhl, S. Update to: Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. In: M. McClelland and A.B. Pardee (Eds.) Expression Genetics: Accelerated and high-throughput methods. Eaton Publishing Co., Natick. (1999) 222-223.

69. Cano, F., Liljeqvist, S., Nguyen, T.N., Samuelson, P., Bonnefoy, J.-Y., Ståhl, S. and Robert, A. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery.FEMS Immunol. Med. Microbiol. 25:289-298(1999).

68. Haddad, D., Liljeqvist, S., Ståhl, S., Hansson, M., Perlmann, P., Ahlborg, N. and Berzins, K. Characterization of antibody responses to a Plasmodium falciparum blood stage antigen induced by a DNA prime/protein boost immunization protocol. Scand. J. Immunol. 49:506-514(1999).

67. Ståhl, S., Nilsson, J., Hober, S., Uhlén, M. and Nygren, P.Å. Affinity fusions, gene expression. In: M. C. Flickinger and S. W. Drew (Eds.) The Encyclopepia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation, Vol. 1, John Wiley and Sons Inc., New York, (1999) 49-63.

66. Hansson, M., Ringdahl, J., Robert, A., Power, U., Goetsch, L., Nguyen, T. N., Uhlén, M., Ståhl, S. and Nygren, P.-Å. An in vitroselected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 4: 237-252 (1999).

65. Liljeqvist, S., Cano, F., Nguyen., T., Uhlén, M., Robert, A. and Ståhl, S. Surface-display of functional fibronectin binding domains on Staphylococcus carnosus. FEBS Letters 446:299-304(1999).

64. Haddad, D., Snounou, G., Mattei, D., Enamorado, I. G., Figueroa, J., Ståhl, S. and Berzins, K. Limited genetic diversity of Plasmodium falciparumin field isolates from Honduras.Am. J. Trop. Med. Hyg. 60: 30-34 (1999).

63. Andersson, C., Sandberg, L., Murby, M., Sjölander, A., Lövgren-Bengtsson, K. and Ståhl, S. General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation. J. Immunol. Meth. 222:171-182 (1999).

62. Ståhl, S., Odeberg, J., Larsson, M., Røsok, Ø., Hansen Ree, A. and Lundeberg, J. Solid-phase differential display and bacterial expression systems in selection and functional analysis of cDNAs. Meth. Enzymol. 303:495-511(1999).

61. Libon, C., Corvaïa, N., Haeuw, J.-F., Nguyen, T.N., Ståhl, S., Bonnefoy, J.-F. and Andréoni, C. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. Vaccine 17:406-414 (1999).

60. Norrander, J., Larsson,. M., Ståhl, S., Höög, C. and Linck, R. Expression of ciliary tektins in brain and sensory development.J. Neuroscience 18:8912-8918 (1998).

59. Sjölander, A., Ahlborg, N., Ståhl, S. and Andersson, R. Characterization of the immune responses to experimental polyvalent subunit vaccines assembled in immunostimulating complexes (iscoms). Molec. Immunol. 35: 159-166 (1998).

58. Haddad, D., Liljeqvist, S., Ståhl, S., Perlmann, P., Berzins, K. and Ahlborg, N. Differential induction of immunoglobulin G subclasses by immunization with DNA vectors encoding or lacking a signal sequence. Immunol. Lett. 61:201-204 (1998).

57. Jonasson, P., Nygren, P.-Å, Johansson, B.-L., Wahren, J., Uhlén, M. and Ståhl, S. Gene fragment polymerization gives increased yields of recombinant human proinsulin C-peptide. Gene 210:203-210 (1998).

56. Nguyen, T. N., Samuelson, P., Sterky, F., Merle-Poitte, C., Robert, A., Baussant, T., Haeuw, J.-F., Uhlén, M., Binz, H. and Ståhl, S. Chromosomal sequencing using a PCR-based biotin-capture method allowed isolation of the complete gene for the outer membrane protein A of Klebsiella pneumonia. Gene 210:93-101 (1998).

55. Liljeqvist, S., Ståhl, S., Andréoni, C., Binz, H., Uhlén, M. and Murby, M. Fusions to the cholera toxin B subunit: influence on pentamerization and GM1-binding. J. Immunol. Meth. 210:125-136 (1997).

54. Andréoni, C., Goetsch, L., Libon, C., Samuelson, P., Robert, A., Nguyen, T.N., Uhlén, M., Binz, H. and Ståhl, S. Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. BioTechniques23:696-704 (1997).

53. Nilsson, J., Ståhl, S., Lundeberg, J., Uhlén, M. and Nygren, P.-Å. Affinity fusion strategies for detection, purification and immobilization of recombinant proteins. Prot. Exp. Purif.11: 1-16 (1997).

52. Haddad, D., Liljeqvist, S., Ståhl, S., Andersson, I., Perlmann, P., Berzins, K. and Ahlborg, N. Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. FEMS Microbiol. Immunol. 18: 193-202 (1997).

51. Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M. and Nygren, P.-Å. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nature Biotechnol. 15:772-777(1997).

50. Liljeqvist, S., Samuelson, P., Hansson, M., Nguyen, T. N., Binz, H. and Ståhl, S. Surface display of a cholera toxin B subunit on Staphylococcus xylosusand Staphylococcus carnosus. Appl. Environ. Microbiol.63:2481-2488 (1997).

49. Ståhl, S., Samuelson, P., Hansson., M., Andréoni, C., Goetsch, L., Libon, C., Liljeqvist, S., Gunneriusson., E., Binz, H., Nguyen, T.N. and Uhlén, M. Development of non-pathogenic staphylococci as vaccine delivery vehicles. In: J. Wells and G. Pozzi (Eds.) Recombinant Gram-positive bacteria as vaccine vehicles for mucosal immunization. R. G. Landes Biomedical Publishers, Springer-Verlag, New York. (1997) 61-81.

48. Ståhl, S. and Uhlén, M. Bacterial surface display: trends and progress. Trends Biotechnol. 15: 185-192 (1997).

47. Power, U. F., Plotnicky-Gilquin, H., Huss, T., Robert, A., Trudel, M., Ståhl, S., Uhlén, M., Nguyen, T. N. and Binz, H. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230: 155-166 (1997).

46. Sjölander, A., Nygren, P.-Å., Ståhl, S., Berzins, K., Uhlén, M., Perlmann, P., and Andersson, R. The serum albumin binding region of streptococcal protein G: a bacterial fusion partner with carrier-related properties. J. Immunol. Meth.201:115-123 (1997).

45. Ståhl, S. and Nygren, P.-Å. The use of gene fusions to protein A and protein G in immunology and biotechnology. Pathol. Biol. 45:66-76 (1997).

44. Ståhl, S., Nygren, P.-Å. and Uhlén, M. Detection and isolation of recombinant protein based on binding affinity of reporter: protein A. In:R.S. Tuan (Ed.) Methods in Molecular Biology Vol. 63, Recombinant Proteins: Detection and Isolation Protocols. Humana Press. Totowa, NJ (1997) 103-118.

43. Ståhl, S., Nygren, P.-Å. and Uhlén, M. Strategies for gene fusion. In:R.S. Tuan (Ed.) Methods in Molecular Biology Vol. 62, Recombinant Gene Expression Protocols. Humana Press Inc. Totowa, NJ (1997) 37-54.

42. Nilsson, J., Larsson, M., Ståhl, S., Nygren, P.-Å. and Uhlén, M. Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. J. Molec. Recognit.9:585-594 (1996).

41. Nilsson, J., Jonasson, P., Samuelsson, E., Ståhl, S. and Uhlén, M. Integrated production of human insulin and its C-peptide. J. Biotechnol.248: 241-250 (1996).

40. Robert, A., Samuelson, P., Andréoni, C., Bächi, T., Uhlén, M. Binz, H., Nguyen, T. N. and Ståhl, S. Surface-display on staphylococci: a comparative study. FEBS Letters390:327-333 (1996).

39. Larsson, M., Brundell, E., Nordfors, L., Höög, C., Uhlén, M. and Ståhl, S. A general bacterial expression system for functional analysis of cDNA-encoded proteins. Prot. Exp. Purif.7:447-457 (1996).

38. Ahlborg, N., Iqbal, J., Björk, L., Ståhl, S., Perlmann, P. and Berzinz, K. Plasmodium falciparum: Differental parasite growth inhibition mediated by antibodies to the antigens Pf332 and Pf155/RESA. Exp. Parasitol. 82:155-163 (1996).

37. Jonasson, P., Nilsson, J., Samuelsson, E., Moks, T., Ståhl, S. and Uhlén, M. Single-step trypsin cleavage of a fusion protein to obtain human insulin and its C-peptide. Eur. J. Biochem.236:656-661 (1996).

36. Gunneriusson, E., Samuelson, P., Uhlén, M., Nygren, P.-Å. and Ståhl, S. Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol.178: 1341-1346 (1996).

35. Murby, M., Uhlén, M. and Ståhl, S. Upstream strategies to minimize proteolytic degradation upon recombinant production in Escherichia coli. Prot. Expr. Purif. 7: 129-136 (1996).

34. Liljeqvist, S., Haddad, D., Berzins, K., Uhlén, M. and Ståhl, S. A novel expression system for Salmonella typhimuriumallowing high production levels, product secretion and recovery. Biochem. Biophys. Res. Comm. 218:356-359 (1996).

33. Haddad, D., Liljeqvist, S., Kumar, S., Hansson, M., Ståhl, S., Perlmann, H., Perlmann, P. and Berzins, K. Surface-display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium: and its implications for immunogenicity. FEMS Immunol. Med. Microbiol.12:175-186 (1995).

32. Berzins, K., Adams, S., Broderson, J.R., Chizzolini, C., Hansson, M., Lövgren, K., Millet, P., Morris, C.L., Perlmann, H., Perlmann, P., Sjölander, A., Ståhl, S., Sullivan, J.S., Troye-Blomberg, M., Wåhlin-Flyg, B. and Collins, W.E. Immunogenicity in Aotusmonkeys of ISCOM formulated repeat sequences from the Plasmodium falciparumasexual blood stage antigen Pf155/RESA. Vaccine Research 4: 121-133 (1995).

31. Nguyen, T.N., Gourdon, M.-H., Hansson, M., Robert, A., Samuelson, P., Libon, C., Andréoni, C., Nygren, P.-Å., Binz, H., Uhlén, M. and Ståhl, S. Hydrophobicity engineering to facilitate surface-display of heterologous gene products on Staphylococcus xylosus. J. Biotechnol. 47: 207-219(1995).

30. Ahlborg, N., Iqbal, J., Hansson, M., Uhlén, M., Mattei, D., Perlmann, P., Ståhl, S. and Berzins, K. Immunogens containing sequences from antigen Pf332 induce Plasmodium falciparum-reactive antibodies which inhibit parasite growth but not cytoadherence. Parasite Immunol. 17: 341-352 (1995).

29. Murby, M., Samuelsson, E., Nguyen, T., Mignard, L., Power, U., Binz, H., Uhlén, M. and Ståhl, S. Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem.230:38-44 (1995).

28. Frost, P., Håvarstein L.S., Lygren, B., Ståhl, S., Endresen, C. and Christie, K.E. Mapping of neutralizing epitopes on infectious pancreatic necrosis viruses (IPNV) with monoclonal antibodies and deleted fragments of VP2. J. Gen. Virol. 76:1165-1172(1995).

27. Samuelson, P., Hansson, M., Ahlborg, N., Andréoni, C., Götz, F., Bächi, T., Nguyen, T.N., Binz, H., Uhlén, M. and Ståhl, S. Cell-surface display of recombinant proteins on Staphylococcus carnosus. J. Bacteriol. 177:1470-1476 (1995).

26. Murby, M., Nguyen, T.N., Binz, H., Uhlén, M. and Ståhl, S. Production and recovery of recombinant proteins of low solubility. In:D.L. Pyle (Ed.) Separations for Biotechnology 3: 336-344, Bookcraft Ltd. Bath, UK (1994).

25. Ahlborg, N., Andersson, R. Ståhl, S., Hansson, M., Andersson, I., Perlmann, P. and Berzins, K. B- and T-cell responses in congenic mice to repeat sequences of the malarial antigen Pf332: Effects of the number of repeats. Immunol. Lett. 40: 147-155 (1994).

24. Nygren, P.-Å., Ståhl, S. and Uhlén, M. Engineering proteins to facilitate bioprocessing. Trends Biotechnol. 12: 184-188 (1994).

23. Hansson, M., Ståhl, S., Hjorth, R., Uhlén, M. and Moks, T. Single-step recovery of a secreted recombinant protein by expanded bed adsorption. Nature Biotechnol. 12: 285-288 (1994).

22. Nguyen, T.N., Uhlén, M. and Ståhl, S. De novogene assembly using a paramagnetic solid support. In:M. Uhlén, E. Hornes, Ø. Olsvik (Eds.) Advances in Biomagnetic Separation: 73-78, Eaton Publishing Co., Natick. (1994).

21. Ståhl, S., Nygren, P.-Å. and Uhlén, M. Impact of genetic engineering on the production of recombinant proteins. In:L. Alberghina, L. Frontali, P. Sensi (Eds.) Proceedings of the 6th European Congress on Biotechnology: 811-816, Elsevier, Amsterdam. (1994).

20. Lepage, P., Heckel, C., Humbert, S., Ståhl, S. and Rautmann, G. Recombinant technology as alternative to chemical peptide synthesis: Expression and characterisation of HIV1-REV recombinant peptides. Anal. Biochem. 213: 40-48 (1993).

19. Sjölander, A., Ståhl, S. and Perlmann, P. Bacterial expression systems based on protein A and protein G designed for the production of immunogens, applications to Plasmodium falciparum malaria antigens.ImmunoMethods 2: 79-92(1993).

18. Nguyen, T.N., Hansson, M., Ståhl, S., Bächi, T., Robert, A., Domzig, W., Binz, H. and Uhlén, M. Cell-surface display of heterologous epitopes on Staphylococcus xylosusas a potential delivery system for oral vaccination. Gene 128:89-94 (1993).

17. Ståhl, S., Nygren, P.-Å., Sjölander, A. and Uhlén, M. Engineered bacterial receptors in immunology. Curr. Opin. Immunol. 5:272-275 (1993).

16. Sjölander, A., Ståhl, S., Lövgren, K., Hansson, M., Cavelier, L., Walles, A., Helmby, H., Wåhlin, B., Morein, B., Uhlén, M., Berzins, K., Perlmann, P. and Wahlgren, M. Plasmodium falciparum: The immune response in rabbits to the clustered-asparagine-rich-protein (CARP) after immunization in Freund's adjuvant or immunostimulating complexes (ISCOMs). Exp. Parasitol. 76:134-145 (1993).

15. Ståhl, S., Hansson, M., Ahlborg, N., Nguyen, T.N., Liljeqvist, S., Lundeberg, J. and Uhlén, M. Solid-phase gene assembly of constructs derived from the Plasmodium falciparum malaria blood-stage antigen Ag332. BioTechniques 14:424-434(1993).

14. Hansson, M., Ståhl, S., Nguyen, T.N., Bächi, T., Robert, A., Binz, H., Sjölander, A. and Uhlén, M. Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus. J. Bacteriol. 174: 4239-4245 (1992).

13. Ståhl, S. Bacterial expression systems designed for the production of immunogens applied to Plasmodium falciparum malaria antigens. Doctoral Thesis ISBN 91-7170-085-4, Royal Institute of Technology, Stockholm (1992).

12. Uhlén, M., Hultman, T., Wahlberg, J., Lundeberg, J., Bergh, S., Pettersson, B., Holmberg, A., Ståhl, S. and Moks, T. Semi-automated solid-phase DNA sequencing.Trends Biotechnol. 10: 52-55 (1992).

11. Ståhl, S., Nygren, P.-Å. and Uhlén, M. Genetic strategies for protein purification. In: H. Jörnvall, J.-O. Höög, A.-M. Gustavsson (Eds.), Methods in Protein Sequence Analysis: 313-320, Birkhäuser Verlag, Basel (1991).

10. Cavelier, L., Sjölander, A., Åslund, L., Ahlborg, N., Helmby, H., Ståhl, S., Wåhlin, B., Berzins, K., Perlmann, P., Uhlén, M., Pettersson, U. and Wahlgren, M. The Plasmodium falciparumclustered-asparagine-rich-protein is a malaria vaccine candidate. In: R.M. Chanock, H.S. Ginsberg, F. Brown, R.A. Lerner (Eds.), Vaccines 91: 375-379, Cold Spring Harbor Laboratory Press, New York (1991).

9. Sjölander, A., Lövgren, K., Ståhl, S., Åslund, L., Hansson, M., Nygren, P.-Å., Larsson, M., Hagstedt, M., Wåhlin, B., Berzins, K., Uhlén, M., Morein, B. and Perlmann, P. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparumantigen Pf155/RESA. Vaccine 9:443-450 (1991).

8. Ståhl, S., Nygren, P.-Å. and Uhlén, M. Protein fusions for the purification and stabilization of recombinant proteins. In:Bioseparations '90; New technologies in upstream and downstream processing: 47-54, IBC Technical Services Ltd, Cambridge (1990).

7. Ståhl, S., Sjölander, A., Hansson, M., Nygren, P.-Å., and Uhlén, M. A general strategy for polymerization, assembly and expression of epitope-carrying peptides applied on the Plasmodium falciparumantigen Pf155/RESA. Gene 89:187-193 (1990).

6. Sjölander, A., Ståhl, S., Nygren, P.-Å., Åslund, L., Ahlborg, N., Wåhlin, B., Scherf, A., Berzins, K., Uhlén, M. and Perlmann, P. Immunogenicity and antigenicity in rabbits of a repeated sequence of the Plasmodium falciparumantigen Pf155/RESA fused to two IgG-binding domains of stahylococcal protein A. Infection and Immunity  58:854-859 (1990).

5. Hultman, T., Murby, M., Ståhl, S., Hornes, E. and Uhlén, M. Solid phase in vitromutagenesis using plasmid DNA template. Nucleic Acids Res. 18:  5107-5112 (1990).

4. Ståhl, S., Sjölander, A., Nygren, P.-Å., Berzins, K., Perlmann, P. and Uhlén, M. A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparumantigen Pf155/RESA. J. Immunol. Methods 124:43-52 (1989).

3. Hultman, T., Ståhl, S., Hornes, E. and Uhlén, M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 17:4937-4946 (1989).

2. Hultman, T., Ståhl, S., Moks, T. and Uhlén, M. Approaches to solid phase DNA sequencing. Nucleos. & Nucleot. 7:629-638 (1988).

1. Ståhl, S., Hultman, T., Olsson, A., Moks, T. and Uhlén, M. Solid phase DNA sequencing using the biotin-avidin system. Nucleic Acids Res. 16:3025-3038 (1988).